BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsEarnings

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher

Open original release

Related news

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

GERNGeron2026-05-06 11:00 EST

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

CAPRCapricor Therapeutics2026-05-04 20:05 EST

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

View all latest news

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a gene-therapy company focused on rare pediatric and hematologic diseases. Its story is built around using advanced genetic medicine to address severe inherited conditions.

Recent company news

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKTRocket Pharmaceuticals2026-03-27 11:00 EST

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-02-23 12:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Stock data

Close
3.25 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States